Toronto - BD Diagnostics, a segment of BD (Becton, Dickinson and Company), demonstrated today at the 107th General Meeting of the American Society for Microbiology the BD Phoenix™ AP, an automated sample preparation instrument.
The BD Phoenix AP instrument is designed to augment the BD Phoenix™ Automated Microbiology System, which is able to consistently identify more than 300 clinically relevant bacteria and assess the pathogens' resistance and susceptibility to antibiotic treatments in less than 16 hours.
The growing shortage of highly skilled laboratory technicians over the last decade has resulted in the need for improved laboratory automation. The BD Phoenix AP instrument reduces hands-on time for upfront sample preparation and maximizes workflow productivity. In addition, the system provides automated inoculum standardization, which helps to minimize variability from technician to technician.
"The speed, efficiency and standardization of the BD Phoenix AP instrument makes the BD Phoenix system attractive to both medium- and high-volume microbiology laboratories," said David Panneton, Worldwide Vice President of Marketing, BD Diagnostics.
BD anticipates the commercial availability of the BD Phoenix AP instrument within the next 14 months.
About BD Phoenix™
The BD Phoenix system enables hospital laboratories to perform identification (ID) and antimicrobial susceptibility testing (AST) for identifying infectious organisms of human clinical significance and the antibiotics to which they are resistant and/or susceptible. Additional features include on-demand loading, single or batch processing, continuous monitoring and custom antibiotic panels, giving users flexibility to test as little as one organism, or as many as 100. The system provides a straightforward, logical, flexible system for users of all skill levels. The BD Phoenix system's efficient design reduces maintenance, saves technical hours and minimizes downtime. It also incorporates a state-of-the-art, knowledge-based system, which creates less room for human error and results in better patient outcomes. Launched in 2001, the BD Phoenix system is utilized by more than 675 medical laboratories.
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.